At doses well below the maximum studied in its pivotal program, CagriSema still produced roughly one-fifth of body weight lost: both the 1.7 mg/1.7 mg and 1.0 mg/1.0 mg combinations delivered estimated average weight loss of about 21% at 68 weeks in the phase 3 REDEFINE 9 trial, compared with 2.0% on placebo. That near-identical response across a meaningful dose gap is what makes the data worth scrutinizing, because it raises a practical question for future prescribing: if lower doses match the top line, does the full 2.4 mg/2.4 mg ceiling add much beyond tolerability headroom?
The trial enrolled 309 adults with overweight or obesity and no diabetes, using a 68-week, placebo-controlled, double-blind design. REDEFINE 9 is the first phase 3 trial in the program to test doses below the 2.4 mg/2.4 mg maximum. Under the efficacy estimand (what happens if everyone stays on treatment), Under the efficacy estimand, roughly 70% of participants at both doses hit at least 15% body weight reduction; about half or just over half reached 20% or more (51.3% at 1.7 mg/1.7 mg and 48.3% at 1.0 mg/1.0 mg). The more conservative treatment-regimen estimand, which counts dropouts as they were, still showed 19.4% and 18.6% average loss for the 1.7 mg and 1.0 mg arms respectively. Discontinuation due to adverse events was low, at 2.9% and 4.9% for the two active doses, comparable to the 4.9% seen with placebo, with gastrointestinal events the most common complaint and mostly mild to moderate.
The strategic context for these numbers sits inside a tighter window than it appears. Novo filed an NDA for CagriSema 2.4 mg/2.4 mg with the FDA in December 2025, with a decision expected in the fourth quarter of 2026. That application is what moves toward approval; REDEFINE 9 is not part of that pivotal submission but informs the clinical picture around dose flexibility. Clinicians routinely titrate GLP-1 based drugs below their approved maximums when patients experience side effects, and evidence that lower fixed combinations hold meaningful efficacy gives prescribers something concrete to reason from, rather than extrapolating down from a single approved dose.
The trial was not powered to detect differences between the two active doses, so the near-identical outcomes do not establish equivalence. What the data do establish is that the floor of CagriSema’s tested range still clears the threshold most obesity medicine specialists consider clinically meaningful. A decision on the 2.4 mg/2.4 mg application is expected in Q4 2026, which will be the first step toward any CagriSema reaching patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
